

AJOONI BIOTECH LIMITED

Regd. Office: D-118, Industrial Area, Phase-VII, Mohali-160055 (Pb.)
Phone: 0172-5020758-69 Website: www.ajoonibiotech.com
E-mail: ajooni.biotech@gmail.com / info@ajoonibiotech.com

Date: 13.10.2018

To,
Manager- Listing Department
EMERGE PLATFORM OF NSE
National Stock Exchange of India Ltd
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400051

Scrip Code: AJOONI

Subject: Statement of deviation under Regulation 32(8) of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015

Dear Sir/Madam,

We enclose herewith the Statement of Deviation under Regulation 32(8) of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015 for the period ended on 30th September, 2018.

Kindly take the same on your record.

Thanking You,

Yours Truly,

For, AJOONI BIOTECH LIMITED

For AJCONI BIOTECH LTD.

Jasjot Singh

Director

Managing Director

DIN: 01937631

Enclosure: Statement of deviation under Regulation 32(8) of the SEBI (LODR) Regulations, 2015

Works: G.T. Road, Khanna-141401 (Punjab) INDIA



AJOONI BIOTECH LIMITED

Regd. Office: D-118, Industrial Area, Phase-VII, Mohali-160055 (Pb.) Phone: 0172-5020758-69 Website: www.ajoonibiotech.com E-mail: ajooni.biotech@gmail.com / info@ajoonibiotech.com

Date: 13.10.2018

To, Manager-Listing Department EMERGE PLATFORM OF NSE National Stock Exchange of India Ltd Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex, Bandra (E) Mumbai - 400051

Scrip Code: AJOONI

Subject: Statement of deviation(s) or Variation(s) under Regulation 32(8) of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015.

Dear Sir/Madam,

Ajooni Biotech Limited has allotted 2196000 equity shares of face value of Rs. 10/- per equity share at an issue price of Rs. 30.00/- (Inclusive of security premium of Rs. 20/-) per equity share through Initial Public Offering (IPO). The purpose and object of the issue were to meet Working Capital Requirement and General Corporate Purposes.

Pursuant to Regulation 32(8) of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015 we hereby state that there have been no deviation(s) or Variation(s) in the utilization of public issue proceeds and entire fund raised from the above said issue has been utilized/ to be utilized for the purpose for which they were issued.

Please take the same on your record.

Thanking You,

Yours Truly,

For, AJOONI BIOTECH LIMITED

For AJOONI BIOTECH LTD.

-170+ 1ph

Jasjot Singh

Managing Director

DIN: 01937631